THE LOCAL TREATMENT OF BURNS WITH ANTIBIOTICS

• Monafo, 1976 - silver sulphadiazine (1%) + cerium nitrates (2.2%)

As silver sulphadiazine offered insufficient protection against the growth of Gram-positive bacteria in patients with extensive burns, a combination was introduced with cerium nitrate (a rare earth metal), in the belief that together the two substances might have a synergic effect.13 The results in the literature, however, are not consistent but contradictory, both in vitro and in vivo.8,12,14 One of the advantages is thought to be the hardening of the eschar due to the precipitation of calcium carbonate and phosphate caused by cerium. The calcification of the eschar would block bacterial colonization and also permit a long delay (8-12 weeks) before proceeding to surgery.15 But who is willing to wait all this time before operating on a major burns victim?

• Slow release silver (Acquacel Ag; Acticoat).

Currently it is believed that silver, in the ionic form used in former formulations (Ag+), is deactivated by the organic fluids in the lesions and must therefore be frequently replaced. Thus, it is the constant replacement through frequent medications that ensures its effectiveness. The new formulations, in which silver is present in either ionic (Acquacel Ag) or nanocrystalline form, allow further release of silver when this is used up in the interaction with the lesion. The continuous release of silver makes it possible to leave the medication in situ for a few days (3 to 7), with decreased mechanical trauma for the patient and decreased nursing time. However, these procedures make it more difficult to inspect the lesion.16 Antibacterial activity towards E-MRSA, Pseudomonas aeruginosa, and Staphylococcus aureus has been reported.1 It is however too early to assess the effect on bacterial resistance, in view of its current non-routine use - the first study on the bacterial resistance caused by silver sulphadiazine appeared at least ten years after it began to be used, and for at least four years no such phenomena were reported.

Local treatment of burns with antibiotics

Our protocol for the local treatment of burns consists of bathing in running water with debridement (on hospitalization, frequently during the course of the disease, and before surgery) and successive medication with antibiotics for topical or systemic use. With regard to partial-thickness burns, the most frequently used routine treatments are with gentamicin, rifamycin S.V., and the chloramphenicol-collagenase association. A multi-centre study (conducted in 11 Italian burn centres) in the years 1992-1993, published in 1994,17 highlighted chloramphenicol’s absolute lack of antibacterial activity, meaning that when chloramphenicol is associated with collagenase it adds nothing to the latter’s activity (enzymatic debridement). Conversely, both gentamicin (which we use for brief periods and for exposed face burn treatment) and rifamycin S.V. (also used for brief periods and as a compress) maintain good antibacterial activity. Now, ten years after the above-mentioned study, a new multi-centre study would be very useful.

In full-thickness burns with necrotic eschar in elderly or diabetic patients, or when the location of the burn, its extent, and the patient’s general conditions are so compromised that surgical escharectomy is risky, we use salicylate Vaseline in various concentrations (5-20%), impregnated with antibiotics, applied through incisions in the eschar itself to facilitate penetration both in and under it. The initial choice of which antibiotic to add to the salicylate Vaseline for a specific patient is made on the basis of the results of the antibiograms carried out on germs isolated from the burns of patients hospitalized in the immediately previous period. Subsequently, the antibiotic can be used to which any germs isolated from the patient are sensitive.

In full-thickness burns with granulating surfaces, before or during completion of surgical therapy, we use a fatty antibiotic-impregnated gauze as a compress, in relation to the antibiogram. During the process of becoming chronic, when there are limited residual areas of deepithelialization and/or infected granulation (generally by Staphylococcus aureus), these are treated with polyurethane foam (which associates debriding action with absorption of burn secretions) and with the antibiotic to which the germ has proved sensitive. As a final point, a gradual and predetermined release system has been devised that guarantees an antibiotic concentration which maintains aseptic conditions for five days following a single administration associated with keratinocyte sheets. The antibiotic we used, applied on a polymer coated with a drug-permeable membrane, was vancomycin, which thus proved to be non-toxic to cultured keratinocytes.

Analysis of burn patient data in the period 2000-2003

Our analysis regarded patients of all ages and burned body surface areas hospitalized in our burns centre during the period 2000-2003.

Table I presents the cases of septicaemia (in parentheses) as well as the total number of patients distributed by age and burn extent.

As can be seen, the number of cases of septicaemia - as might be expected - increased in relation to the extent of the burn.

In particular, in the group of burns between 15 and 50% TBSA, the average burn surface was 35% (SD ± 10). Although the septicaemia rate (0.26%) in the group of patients with burns in less than 15% TBSA was predictably very low, about 40% of such patients were treated surgically because their burns, though limited in area, involved a higher risk of infection, as they were deep and subject to more intense manipulation (Table II).

The patients subjected to surgery included many with pathologies favouring infection who presented a dual risk - there were altogether 64 of these immunodepressed patients (8.5%) (Table III).

The main germs isolated from the blood cultures were, as might have been expected, Staphylococcus aureus and Pseudomonas aeruginosa (Table IV), accompanied by other Gram-positive (Table V) and Gram-negative (Table VI) germs, generally opportunistic pathogens, in cases of septicaemia that in the majority of cases were polymicrobial.

Table VII shows the distribution of deaths in relation to age and all burn percentages, with a comparison to predicted mortality (Probit analysis). As can be seen, the best results were obtained in the group of patients over 65 years old, with a reduction in the death rate of about 50%. Good results were also obtained in other age groups.22 To conclude (Table VIII), while not all deaths were caused by septicaemia, not all septicaemic patients died - among our cases septicaemia was not in fact the leading cause of death.

Conclusion

After bacterial colonization, infection, and sepsis of the burn area, septicaemia is the severest form of infection arising from contamination of a burn. This contamination, whether originating from the patient (skin, faeces, oropharynx, 16%) or from the environment, medical personnel, or other patients (84%), can be counteracted only by using various means at the same time. The principal means are the sterility of the environment and of the medications, the strengthening of the organism’s defence mechanisms, and surgical coverage of the burn surface.23 Among these remedies, pharmacological anti-infective treatment clearly plays an important role. This must make use of non-toxic material possessing an antibacterial effect that targets the micro-organism in question, in non-fluctuating concentrations at the level of the lesion and capable of encouraging selection of resistant micro-organisms. The analysis of the main antiseptics in use and the results we obtained as regards general mortality and secondary mortality due to septicaemia provide evidence of the advisability of continuing to use antibiotics in the local treatment of burns.

RESUME. Les Auteurs, après avoir analysé les principaux antiseptiques utilisés pour le traitement local des brûlures et souligné leur toxicité et les limitations de leur efficacité antibactérienne, décrivent le protocole thérapeutique utilisé dans leur centre des brûlés (où le traitement antibactérien consiste exclusivement en des antibiotiques pour l’emploi local et systémique). Ils considèrent en outre les données sur la mortalité réelle et prévue, et la mortalité due à la septicémie pendant les années 2000-2003.

Bibliography

1. Dunn K., Edwards-Jones V. (eds): The role of Acticoat with nanocrystalline silver in the management of burns. Burns, 30 (suppl. 1): S1-S9, 2004.
2. Monafo W.W., Ayvazian V.H.: Terapia clinica. Clin. Chir. Nord Am., 11: 1288-1305, 1980.
3. Agolini G., Micali G., Raitano A.: Antisettici e chemioterapici nella terapia topica delle ustioni. Riv. Ital. Chir. Plastica, 30: 233-67, 1998.
4. Nicoletti G., Nicolosi V.M.: “Dizionario di batteriologia umana normale e patologica” (3rd edition), Menarini, Florence, 1998.
5. Lloyd J.R.: Ustioni: progressi nella terapia e prospettive di studio. Clin. Chir. Nord Am., 10: 133-52, 1978.
6. Winkley J.H., Weibel L., Davies W.D., Johnston M.: Il trattamento locale delle ustioni. Clin. Chir. Nord Am., 1: 1416-25, 1969.
7. Trong-Duo Chou, Gibran N.S., Urdahl K., Lin E.Y., Heimbach D., Engrav L.H.: Methemoglobinaemia secondary to topical silver nitrate therapy - a case report. Burns, 25: 549-52, 1999.
8. Klasen H.J.: A historical review of the use of silver in the treatment of burns. II. Renewed interest for silver. Burns, 26: 131-38, 2000.
9. Eldad A., Neuman A., Weinberg A., Benmeir P., Rotem M., Wexler M.R.: Silver-sulphadiazine-induced haemolytic anaemia in a glucose-6-phosphate dehydrogenase-deficient burn patient. Burns, 17: 430-2, 1991.
10. Fraser-Moodie A.: Sensitivity to silver in a patient treated with silver sulphadiazine (Flamazine). Burns, 18: 74-5, 1992.
11. Gamelli R.L., Paxton T.P., O’Reilly M.: Bone marrow toxicity by silver sulphadiazine. Surg. Gynec. Obstet., 177: 115-20, 1993.
12. De Gracia C.G.: An open study comparing topical silver sulphadiazine and topical sulphadiazine-cerium nitrate in the treatment of moderate and severe burns. Burns, 27: 67-74, 2001.
13. Monafo W.W., Ayvazian V.H., Skinner A.M.: Control of infection in major burn wounds by cerium nitrate/silver sulphadiazine. Burns, 3: 104-7, 1976.
14. Di Francesco-Eklund F., Barisoni D.: Sulfadiazina argento vs cerio sulfadiazina: studio batteriologico. Abstracts 12th Congresso Nazionale SIUST, Catania, 1996.
15. Boeckx W., Blondeel Ph. N., Vandersteen K., Dewolf-Peteers C., Schmitz A.: Effect of cerium nitrate-silver sulphadiazine on deep dermal burns: A histological hypothesis. Burns, 18: 456-62, 1992.
16. Montone A., Marianetti M.: La medicazione delle ustioni dermiche con Acquacel Ag. Nostra esperienza. Wound Care Times, 2: 2-6, 2004.
17. Dioguardi et al.: Monitoraggio microbiologico del paziente ustionato e studio della citotossicità degli antisettici topici di più comune impiego clinico. Atti 11° Congresso Nazionale SIUST, pp. 13-38, Bari, November 1994.
18. Masellis M.: Association of salicylic Vaseline with antiseptics or antibiotics in topical treatment of burns. In: May and Dogo (eds), “Care of the Burn Wound”, pp. 1-6, International Congress, Geneva, 1983, Karger, Basel, 1985.
19. Napoli B., D’Arpa N., Iaia A., Sferrazza G., Masellis M.: Antibiotic salicylate vaseline: A topical treatment of choice in burned diabetic patients? Annals of Burns and Fire Disasters, 12: 146-9, 1999.
20. Giannola L.I., De Caro V., Adragna E., Giandalia G., Giannola G., D’Arpa N., Napoli B., D’Amelio L., Genovese M., Lombardo C., Masellis M.: Applicazione di un sistema di rilascio modificato contenente antibiotici associato a lamine di cheratinociti poste su pazienti ustionati. Part I. Atti 47° Convegno Nazionale SICPRE, Palermo, pp. 9-12, September 1998.
21. D’Arpa N., Napoli B., D’Amelio L., Genovese M., Masellis M., Giannola L.I., De Caro V., Adragna E., Giandalia G., Giannola G.: Applicazione di un sistema di rilascio modificato contenente antibiotici associato a lamine di cheratinociti poste su pazienti ustionati. Part II, Atti 47° Convegno Nazionale SICPRE, Palermo, pp. 13-15, September 1998.
22. Rashid A., Khanna A., Gowar J.P., Bull J.P.: Revised estimates of mortality from burns in the last 20 years at the Birmingham burns centre. Burns, 27: 723-30, 2001.
23. Barisoni D.: “Le ustioni e il loro trattamento”, Piccin, Padua, 1984.